TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Evaluation of Cow Milk-Based Formulas - Functional Proteins
Brief Summary: The purpose of this study is to look at the function of infant formula components to optimize the nutritional content and functionality of a marketed routine infant formula.


Options:
A: Arm Label: Study Formula (SF); Type: EXPERIMENTAL; Interventions: Other: Study Formula (SF) | Arm Label: Comparator Formula (CF); Type: ACTIVE_COMPARATOR; Interventions: Other: Comparator Formula (CF) | Arm Label: Human Milk Reference Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Study Formula (SF); Assigned to Arm(s): Study Formula (SF) | Intervention Type: OTHER; Name: Comparator Formula (CF); Assigned to Arm(s): Comparator Formula (CF)
B: Arm Label: Lower protein formula; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Lower protein formula; Higher protein formula | Arm Label: Higher protein formula; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Lower protein formula; Higher protein formula | Arm Label: Breastfed reference group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Lower protein formula; Higher protein formula; Assigned to Arm(s): Higher protein formula, Lower protein formula
C: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Other: standard infant formula | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: Test formula | Arm Label: 3; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: standard infant formula; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Test formula; Assigned to Arm(s): 2
D: Arm Label: Experimental milk-based infant formula; Type: N/A; Interventions: N/A | Arm Label: Control milk-based infant formula; Type: N/A; Interventions: N/A | Arm Label: Breastfed Reference Group; Type: N/A; Interventions: N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pharmacogenetic Studies on Attention Deficit Hyperactivity Disorder
Brief Summary: The ultimate goal of this study is to find the association between specific polymorphism of candidate genes and medication response in attention deficit hyperactivity disorder (ADHD) patients. These results will lead the investigators' team: (1) to resolve controversies over inconsistent findings in previous pharmacogenetic studies; (2) to study the medication effect on the neuropsychological functions that are useful candidate endophenotypes for ADHD; (3) to delineate the nature and the effect of gene-gene interaction in the drug response of ADHD patients.


Options:
A: Arm Label: Methylphenidate Transdermal System; Type: EXPERIMENTAL; Interventions: Drug: Daytrana | Intervention Type: DRUG; Name: Daytrana; Assigned to Arm(s): Methylphenidate Transdermal System
B: Arm Label: OROS-methylphenidate; Type: N/A; Interventions: N/A | Arm Label: Atomoxetine group; Type: N/A; Interventions: N/A | Arm Label: Control group; Type: N/A; Interventions: N/A
C: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: methylphenidate HCl | Intervention Type: DRUG; Name: methylphenidate HCl; Assigned to Arm(s): 001
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Methylphenidate HCl, Drug: Risperidone, Behavioral: Parent Management Training (PMT) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate HCl, Behavioral: Parent Management Training (PMT), Drug: Placebo | Intervention Type: DRUG; Name: Methylphenidate HCl; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Parent Management Training (PMT); Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-Blinded Study of IMC-1121B and Best Supportive Care (BSC) Versus Placebo and BSC in the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression on First-Line Platinum- or Fluoropyrimidine-Containing Combination Therapy
Brief Summary: The purpose of this study is to gather information about the use of an investigational drug called Ramucirumab in adenocarcinomas of the stomach or gastroesophageal junction.


Options:
A: Arm Label: EOX; Type: ACTIVE_COMPARATOR; Interventions: Other: EOX | Arm Label: mDCF; Type: ACTIVE_COMPARATOR; Interventions: Other: mDCF | Intervention Type: OTHER; Name: EOX; Assigned to Arm(s): EOX | Intervention Type: OTHER; Name: mDCF; Assigned to Arm(s): mDCF
B: Arm Label: A 850; Type: EXPERIMENTAL; Interventions: Drug: apatinib tablet | Arm Label: B 425; Type: EXPERIMENTAL; Interventions: Drug: apatinib tablet | Arm Label: C pla; Type: PLACEBO_COMPARATOR; Interventions: Drug: apatinib tablet | Intervention Type: DRUG; Name: apatinib tablet; Assigned to Arm(s): A 850, B 425, C pla
C: Arm Label: ramucirumab; Type: EXPERIMENTAL; Interventions: Biological: ramucirumab, Other: Best Supportive Care (BSC) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Other: Best Supportive Care (BSC) | Intervention Type: BIOLOGICAL; Name: ramucirumab; Assigned to Arm(s): ramucirumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: OTHER; Name: Best Supportive Care (BSC); Assigned to Arm(s): Placebo, ramucirumab
D: Arm Label: Pertuzumab + Trastuzumab + Docetaxel; Type: EXPERIMENTAL; Interventions: Drug: Pertuzumab, Drug: Trastuzumab, Drug: Docetaxel | Arm Label: Placebo + Trastuzumab + Docetaxel; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Trastuzumab, Drug: Docetaxel | Intervention Type: DRUG; Name: Pertuzumab; Assigned to Arm(s): Pertuzumab + Trastuzumab + Docetaxel | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Trastuzumab + Docetaxel | Intervention Type: DRUG; Name: Trastuzumab; Assigned to Arm(s): Pertuzumab + Trastuzumab + Docetaxel, Placebo + Trastuzumab + Docetaxel | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Pertuzumab + Trastuzumab + Docetaxel, Placebo + Trastuzumab + Docetaxel

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-Blinded Study of IMC-1121B and Best Supportive Care (BSC) Versus Placebo and BSC in the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression on First-Line Platinum- or Fluoropyrimidine-Containing Combination Therapy
Brief Summary: The purpose of this study is to gather information about the use of an investigational drug called Ramucirumab in adenocarcinomas of the stomach or gastroesophageal junction.


Options:
A: Arm Label: ramucirumab; Type: EXPERIMENTAL; Interventions: Biological: ramucirumab, Other: Best Supportive Care (BSC) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Other: Best Supportive Care (BSC) | Intervention Type: BIOLOGICAL; Name: ramucirumab; Assigned to Arm(s): ramucirumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: OTHER; Name: Best Supportive Care (BSC); Assigned to Arm(s): Placebo, ramucirumab
B: Arm Label: 1- Docetaxel plus Oxaliplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel, Drug: oxaliplatin | Arm Label: 2- Docetaxel plus oxaliplatin plus cetuximab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel, Drug: cetuximab, Drug: oxaliplatin | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): 1- Docetaxel plus Oxaliplatin, 2- Docetaxel plus oxaliplatin plus cetuximab | Intervention Type: DRUG; Name: cetuximab; Assigned to Arm(s): 2- Docetaxel plus oxaliplatin plus cetuximab | Intervention Type: DRUG; Name: oxaliplatin; Assigned to Arm(s): 1- Docetaxel plus Oxaliplatin, 2- Docetaxel plus oxaliplatin plus cetuximab
C: Arm Label: Ramucirumab; Type: EXPERIMENTAL; Interventions: Biological: Ramucirumab, Drug: Oxaliplatin, Drug: Leucovorin, Drug: 5-Fluorouracil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Oxaliplatin, Drug: Leucovorin, Drug: 5-Fluorouracil | Intervention Type: BIOLOGICAL; Name: Ramucirumab; Assigned to Arm(s): Ramucirumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Oxaliplatin; Assigned to Arm(s): Placebo, Ramucirumab | Intervention Type: DRUG; Name: Leucovorin; Assigned to Arm(s): Placebo, Ramucirumab | Intervention Type: DRUG; Name: 5-Fluorouracil; Assigned to Arm(s): Placebo, Ramucirumab
D: Arm Label: Standard taxane therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Taxane | Arm Label: trastuzumab emtansine 2.4 mg; Type: EXPERIMENTAL; Interventions: Drug: trastuzumab emtansine | Arm Label: trastuzumab emtansine 3.6 mg; Type: EXPERIMENTAL; Interventions: Drug: trastuzumab emtansine | Intervention Type: DRUG; Name: Taxane; Assigned to Arm(s): Standard taxane therapy | Intervention Type: DRUG; Name: trastuzumab emtansine; Assigned to Arm(s): trastuzumab emtansine 3.6 mg | Intervention Type: DRUG; Name: trastuzumab emtansine; Assigned to Arm(s): trastuzumab emtansine 2.4 mg

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-Blinded Study of IMC-1121B and Best Supportive Care (BSC) Versus Placebo and BSC in the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression on First-Line Platinum- or Fluoropyrimidine-Containing Combination Therapy
Brief Summary: The purpose of this study is to gather information about the use of an investigational drug called Ramucirumab in adenocarcinomas of the stomach or gastroesophageal junction.


Options:
A: Arm Label: ramucirumab; Type: EXPERIMENTAL; Interventions: Biological: ramucirumab, Other: Best Supportive Care (BSC) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Other: Best Supportive Care (BSC) | Intervention Type: BIOLOGICAL; Name: ramucirumab; Assigned to Arm(s): ramucirumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: OTHER; Name: Best Supportive Care (BSC); Assigned to Arm(s): Placebo, ramucirumab
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Docetaxel, Drug: 5-Fluorouracil, Drug: Oxaliplatin, Drug: folinic acid | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: 5-Fluorouracil, Drug: Oxaliplatin, Drug: folinic acid | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: 5-Fluorouracil; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Oxaliplatin; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: folinic acid; Assigned to Arm(s): 1, 2
C: Arm Label: Olaparib+ paclitaxel; Type: EXPERIMENTAL; Interventions: Drug: Olaparib, Drug: Paclitaxel | Arm Label: Placebo+paclitaxel; Type: PLACEBO_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Placebo | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): Olaparib+ paclitaxel | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Olaparib+ paclitaxel, Placebo+paclitaxel | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo+paclitaxel
D: Arm Label: A 850; Type: EXPERIMENTAL; Interventions: Drug: apatinib tablet | Arm Label: B 425; Type: EXPERIMENTAL; Interventions: Drug: apatinib tablet | Arm Label: C pla; Type: PLACEBO_COMPARATOR; Interventions: Drug: apatinib tablet | Intervention Type: DRUG; Name: apatinib tablet; Assigned to Arm(s): A 850, B 425, C pla

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective Collection of Biological Data of Prognostic Relevance in Patients
Brief Summary: The purpose of the present study is to develop a biological prognostic index in patients with Binet stage A Chronic Lymphocytic Leukemia (CLL) who do not necessitate therapy according to NCI guidelines and to prospectively validate the proposed score system based on the absence/presence of 1, 2 or 3 unfavorable prognostic markers such as cluster of differentiation 38 (CD38) expression, Zap-70 expression and immunoglobulin heavy chain variable region (IgVH) configuration.


Options:
A: N/A
B: Arm Label: Inhalational anesthetic; Type: ACTIVE_COMPARATOR; Interventions: Drug: Inhalational anesthetic | Arm Label: Intravenous anesthetic, propofol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous anesthetic, propofol | Intervention Type: DRUG; Name: Inhalational anesthetic; Assigned to Arm(s): Inhalational anesthetic | Intervention Type: DRUG; Name: Intravenous anesthetic, propofol; Assigned to Arm(s): Intravenous anesthetic, propofol
C: N/A
D: N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Robot-Assisted Upper Limb Rehabilitation in Stroke
Brief Summary: This project consists of two parts: Robotic Rehabilitation Trials, and Study of Outcome Predictors and Clinimetric Attributes. In the first part of study, the investigators aim to (1) investigate the treatment effects of robot-assisted therapy (RAT) in patients with stroke on various outcomes, (2) test the dose-response relations by using two different intensities (higher versus lower intensity RAT), and (3) investigate the effects of the training intensity on a biomarker of oxidative stress. Treatment outcomes will encompass the spectrum of functioning including motor ability, motor control strategies, basic/extended daily functions, mobility, community reintegration, quality of life, and biomarker (8-OHdG). In the second part of study, the purposes are to define the appropriate populations for RAT and to examine the clinimetric properties of clinical measures relevant for use in robotic rehabilitation research. the investigators will identify the clinical predictors that will potentially influence the functional outcomes after interventions. Finally, the investigators will examine and compare the clinimetric properties (e.g., validity and responsiveness) of the clinical measures of rehabilitation outcome to inform selection of test instruments that may detect clinically meaningful change after rehabilitation therapy.


Options:
A: Arm Label: Intensive group; Type: EXPERIMENTAL; Interventions: Procedure: Cognitive rehabilitation | Arm Label: Conventional group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Cognitive rehabilitation | Intervention Type: PROCEDURE; Name: Cognitive rehabilitation; Assigned to Arm(s): Conventional group, Intensive group
B: Intervention Type: OTHER; Name: Robot-assisted therapy; Assigned to Arm(s): N/A
C: Arm Label: ASAP; Type: EXPERIMENTAL; Interventions: Behavioral: Accelerated Skill Acquisition Program (ASAP) | Arm Label: DEUCC; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Dose-Equivalent Usual & Customary Care - DEUCC | Arm Label: UCC; Type: OTHER; Interventions: Behavioral: Usual and Customary Care - UCC | Intervention Type: BEHAVIORAL; Name: Accelerated Skill Acquisition Program (ASAP); Assigned to Arm(s): ASAP | Intervention Type: BEHAVIORAL; Name: Dose-Equivalent Usual & Customary Care - DEUCC; Assigned to Arm(s): DEUCC | Intervention Type: BEHAVIORAL; Name: Usual and Customary Care - UCC; Assigned to Arm(s): UCC
D: Arm Label: Early mobilization; Type: EXPERIMENTAL; Interventions: Other: Early mobilization | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Early mobilization; Assigned to Arm(s): Early mobilization

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Co-Bedding as a Comfort Measure for Twins Undergoing Painful Procedures
Brief Summary: A rising number of preterm twins, at high risk of undergoing repeated medical procedures often without adequate pain relief, are being admitted to Neonatal Intensive Care Units. Skin-to-skin contact between mothers and their infants during painful procedures has been shown to decrease pain and help them stabilize more quickly afterwards. The main question of this study is whether the contact of a twin could provide a similar form of comfort. Sixty-four twin pairs will have an equal chance of undergoing a medically necessary heel stick while being cared for together (co-bedding) or separately. Primary outcome will be physiologic and behavioral pain response. If found to be beneficial, changes to neonatal care practices to include co-bedding may help twins tolerate and recover from painful procedures. Findings will help care providers make recommendations for at risk twins experiencing procedural pain and add to existing theoretical models with respect to the exact mechanism of comfort through touch.


Options:
A: Arm Label: Noanalgesia; Type: SHAM_COMPARATOR; Interventions: Procedure: Water 2mL PO 2 minutes prior to intra-muscular injection | Arm Label: Skin-to-skin; Type: EXPERIMENTAL; Interventions: Procedure: skin-to-skin contact | Arm Label: Glucose; Type: EXPERIMENTAL; Interventions: Procedure: Glucose 25% 2 mL PO 2 minutes prior to injection | Arm Label: Skin&Glucose; Type: EXPERIMENTAL; Interventions: Procedure: neonates will receive skin-to-skin contact beginning 2 minutes after the intra-muscular injection and stopping 2 minutes afterwards. | Intervention Type: PROCEDURE; Name: Water 2mL PO 2 minutes prior to intra-muscular injection; Assigned to Arm(s): Noanalgesia | Intervention Type: PROCEDURE; Name: skin-to-skin contact; Assigned to Arm(s): Skin-to-skin | Intervention Type: PROCEDURE; Name: Glucose 25% 2 mL PO 2 minutes prior to injection; Assigned to Arm(s): Glucose | Intervention Type: PROCEDURE; Name: neonates will receive skin-to-skin contact beginning 2 minutes after the intra-muscular injection and stopping 2 minutes afterwards.; Assigned to Arm(s): Skin&Glucose
B: Arm Label: control; Type: N/A; Interventions: N/A | Arm Label: sucrose; Type: N/A; Interventions: N/A | Arm Label: physical intervention; Type: N/A; Interventions: N/A | Arm Label: physical intervention and sucrose; Type: N/A; Interventions: N/A
C: Arm Label: Co-bedding; Type: EXPERIMENTAL; Interventions: Procedure: Co-bedding (caring for twins in the same incubator) | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Co-bedding (caring for twins in the same incubator); Assigned to Arm(s): Co-bedding
D: Arm Label: OH; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Hernia repair | Arm Label: LH; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Hernia repair | Intervention Type: PROCEDURE; Name: Hernia repair; Assigned to Arm(s): LH, OH

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Co-Bedding as a Comfort Measure for Twins Undergoing Painful Procedures
Brief Summary: A rising number of preterm twins, at high risk of undergoing repeated medical procedures often without adequate pain relief, are being admitted to Neonatal Intensive Care Units. Skin-to-skin contact between mothers and their infants during painful procedures has been shown to decrease pain and help them stabilize more quickly afterwards. The main question of this study is whether the contact of a twin could provide a similar form of comfort. Sixty-four twin pairs will have an equal chance of undergoing a medically necessary heel stick while being cared for together (co-bedding) or separately. Primary outcome will be physiologic and behavioral pain response. If found to be beneficial, changes to neonatal care practices to include co-bedding may help twins tolerate and recover from painful procedures. Findings will help care providers make recommendations for at risk twins experiencing procedural pain and add to existing theoretical models with respect to the exact mechanism of comfort through touch.


Options:
A: Arm Label: Pain Practice Change Booster; Type: EXPERIMENTAL; Interventions: Behavioral: Pain Practice Change Booster Intervention | Arm Label: Usual Care Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Pain Practice Change Booster Intervention; Assigned to Arm(s): Pain Practice Change Booster
B: Arm Label: Standard intervention; Type: SHAM_COMPARATOR; Interventions: Other: standard | Arm Label: clown care; Type: EXPERIMENTAL; Interventions: Behavioral: clown care | Intervention Type: OTHER; Name: standard; Assigned to Arm(s): Standard intervention | Intervention Type: BEHAVIORAL; Name: clown care; Assigned to Arm(s): clown care
C: Arm Label: Co-bedding; Type: EXPERIMENTAL; Interventions: Procedure: Co-bedding (caring for twins in the same incubator) | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Co-bedding (caring for twins in the same incubator); Assigned to Arm(s): Co-bedding
D: Arm Label: Standard Care; Type: SHAM_COMPARATOR; Interventions: Behavioral: Be Sweet to Babies Videos and Pamphlet | Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: MIAS&Q, Behavioral: Be Sweet to Babies Videos and Pamphlet | Intervention Type: BEHAVIORAL; Name: MIAS&Q; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Be Sweet to Babies Videos and Pamphlet; Assigned to Arm(s): Intervention, Standard Care

Answer: C